brl 35135 has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, K; Ida, K; Kato, K; Mizota, M; Murakami, N; Nagao, Y; Takeda, M | 1 |
| Hänninen, V; Huupponen, R; Koulu, M; Rouru, J; Rouvari, T; Savontaus, E; Teirmaa, T; Virtanen, KA | 1 |
2 other study(ies) available for brl 35135 and Insulin Resistance
| Article | Year |
|---|---|
Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents.
Topics: Adipose Tissue; Adrenergic beta-Agonists; Animals; Blood Glucose; Dose-Response Relationship, Drug; Female; Insulin; Insulin Resistance; Lipolysis; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Organ Size; Phenethylamines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rats, Zucker; Stereoisomerism; Tissue Distribution; Weight Gain | 1996 |
Chronic treatment with BRL 35135 potentiates the action of insulin on lipid metabolism.
Topics: Adrenergic beta-Agonists; Animals; Drug Synergism; Hyperinsulinism; Insulin; Insulin Resistance; Lipids; Male; Obesity; Phenethylamines; Rats; Rats, Zucker | 1997 |